

**Enterprise P&T Meeting Committee
July 28, 2025**

Voting Members Present

Christopher Antypas, PharmD	Fury Fecondo, PharmD	Jena Quinn, PharmD
Michael Baer, MD	Emily Kryger, PharmD	Manni Sethi, MD
David Batluck, DO	Kelly Martin, PharmD	Christy Skibicki, MD
Tracey Davis, PharmD	Andrew Peterson, PharmD	Rani Whitfield, MD
Rogers Elebra, PharmD	David Petkash, MD	

Excused Voting Members

Donald Beam, MD	Robert Clifford, MD	Lenaye Lawyer, MD	Eric Peters, PharmD
Floyd (John) Brinley, MD	Loretta Dumontet, MD	Yavar Moghimi, MD	Wayne Weart, PharmD
Kirt Caton, MD	Robert Hockmuth, MD	Michelle Murphy, PharmD	

Invited Guests Present

Christian Andreaggi, PharmD	Rajneel Farley, PharmD	Geraldine Marks, PharmD	Ruth Smith, PharmD
Bethany Baird, CPhT	Seema Gupta, MD	Lauren Megargell, PharmD	Luke Stadler, PharmD
Linda Carreras, CPhT	Katherine Harris, PharmD	Christopher Meny, RPh	Lance Vinci, PharmD
Kathleen Clement	Sheireen Huang, PharmD	Patty Oaster	Arlene Wiseman, PharmD
Patrick DeHoratius, PharmD	Amanda Hunter, PharmD	Sarah Pawlak, PharmD	

Issue	Discussion	Conclusion/Results	Action/ Person Responsible
• Call to order	The meeting was called to order at 6:01 PM EST	Informational Only	Manni Sethi
• Conflict of Interest Disclosures	No conflicts announced	Informational Only	Christopher Meny
• [REDACTED]		[REDACTED]	[REDACTED]
• Review and approval of April P&T Minutes		Committee approved as recommended: Motion: Andrew Peterson Second: David Batluck	
• Old Business			
mResvia AL update	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>CHC:</p> <ul style="list-style-type: none"> Update T3- AL (18 years and older. 	<p>Committee approved as recommended:</p> <p>Motion: David Petkash Second: Kelly Martin</p>	PerformRx will update the criteria and formulary/PDL with any changes

6. New Business			
[REDACTED].CHC Vitamin C ALs	PerformRx makes the following recommendation: [REDACTED].CHC: <ul style="list-style-type: none"> Remove the age limit on the Vitamin C Oral Tablet 250 MG. 	Committee approved as recommended: Motion: David Batluck Second: Rani Whitfield	PerformRx will update the criteria and formulary/PDL with any changes
[REDACTED].CHC QL Addition	PerformRx makes the following recommendation: [REDACTED].CHC: <ul style="list-style-type: none"> Add Kalydeco 25 mg 60 packets per 30-day supply. Ivabradine 5 mg: 90 tablets per 30-day supply Ivabradine 7.5 mg: 60 tablets per 30-day supply 	Committee approved as recommended: Motion: David Batluck Second: Rani Whitfield	PerformRx will update the criteria and formulary/PDL with any changes
Complement Inhibitor PA Criteria	PerformRx makes the following recommendation: <div style="background-color: black; height: 100px; width: 100%;"></div>	Committee approved as recommended: Motion: David Batluck Second: Rani Whitfield	PerformRx will update the criteria and formulary/PDL with any changes

	<ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] <p>■ [REDACTED].CHC:</p> <ul style="list-style-type: none"> • Update the Paroxysmal Nocturnal Hemoglobinuria (PNH) initial authorization criteria to require the presence of a sign or symptom of PNH and to trial the Soliris biosimilar, Epysqli, first. • Update the other criteria section to contain a reference to the newly created IgA Nephropathy criteria. • Add initial authorization requirements to the new indication of Complement 3 Glomerulopathy (C3G) <p>■ [REDACTED]</p> <p>■ [REDACTED]</p>		
--	--	--	--

	<ul style="list-style-type: none"> <ul style="list-style-type: none"> [REDACTED] 		
Myasthenia Gravis PA Criteria	<p>PerformRx makes the following recommendation:</p> <ul style="list-style-type: none"> <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED].CHC:</p>	<p>Committee approved as recommended:</p> <p>Motion: David Batluck Second: Rani Whitfield</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<ul style="list-style-type: none"> • Update the drug list section to include Imaavy. • Update the initial authorization section to also include references to Imaavy. 		
	<div> <div></div> <div></div> <div></div> </div>		
	<div> <div></div> <div></div> <div></div> <div></div> <div></div> <div></div> <div></div> <div></div> <div></div> </div>	<div> <div></div> <div></div> </div>	<div> <div></div> </div>

Immunoglobulin A (IGA) Nephropathy PA Criteria	PerformRx makes the following recommendation: <div data-bbox="459 537 1062 1398"> <div>█ █</div> <div>█</div> <div>█</div> <div>█ █</div> <div>█</div> <div>█ █</div> <div>█</div> <div>█ █</div> <div>█</div> <div>█ █</div> <div>█</div> </div>	Committee approved as recommended: Motion: David Batluck Second: Rani Whitfield	PerformRx will update the criteria and formulary/PDL with any changes
---	---	--	--

	<p>CHC:</p> <ul style="list-style-type: none"> • Approve the Immunoglobulin A (IgA) Nephropathy Agents prior authorization criteria as new criteria. • Retire the Filspari prior authorization criteria it is a part of the new criteria. <p>█</p> <ul style="list-style-type: none"> █ █ █ █ 		
Oncology PA Criteria	<p>PerformRx makes the following recommendation:</p> <p>█</p> <ul style="list-style-type: none"> █ █ █ █ █ █ █ █ 	<p>Committee approved as recommended:</p> <p>Motion: David Batluck Second: Rani Whitfield</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>█ [REDACTED]</p> <p>█.CHC:</p> <ul style="list-style-type: none"> • Approve the Oncology Drugs/Therapies prior authorization criteria clinical changes. • Add an age restriction to be aligned with the package insert or NCCN guidelines. • Update the prescriber restriction to allow a consultation with an oncologist or specialist in the type of cancer being treated. • Update the initial authorization section to require the product is being prescribed at a duration that is within FDA approved/NCCN guidelines. <p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED]</p>		
--	--	--	--

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
7. Drug Review			
A. Therapeutic Class:			
Respiratory Aids and Device	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED].CHC:</p> <ul style="list-style-type: none"> • Make no changes to this class. <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Kelly Martin</p>	No Changes
Bowel Prep Agents	PerformRx makes the following recommendation:	Committee approved as recommended:	PerformRx will update the criteria and formulary/PDL with any changes

	<p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED].CHC:</p> <ul style="list-style-type: none"> • Make no changes to this class. <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] 	<p>Motion: Christopher Antypas Second: Kelly Martin</p>	
[REDACTED]	<p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] 	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p>		
Vascular Endothelial Growth Factor (VEGF) Inhibitors	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> - [REDACTED] - [REDACTED] - [REDACTED] - [REDACTED] - [REDACTED] - [REDACTED] - [REDACTED] - [REDACTED] - [REDACTED] <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Kelly Martin</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	Ophthalmic Conditions prior authorization criteria.		
(b) (6)	[REDACTED]		
(b) (6)	[REDACTED]		
(b) (6)	[REDACTED]		

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED].CHC:</p> <ul style="list-style-type: none"> • Make no formulary changes. <p>[REDACTED]</p> <p>[REDACTED]</p>		
[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	
<p>Ophthalmic Antibiotics and Ophthalmic Antibiotics/Steroids</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Kelly Martin</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED].CHC:</p> <ul style="list-style-type: none"> • Make no formulary changes. <p>[REDACTED]</p> <p>[REDACTED]</p>		
Chelating Agents	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Kelly Martin</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>






















	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED].CHC:</p>		
--	--	--	--

	<ul style="list-style-type: none"> • Make no formulary changes. • Approve the Chelating Agents prior authorization criteria with the following clinical changes: <ol style="list-style-type: none"> a. Update the drug list section to remove Bal in Oil as it has been discontinued. <div style="background-color: black; width: 100px; height: 100px; margin-top: 10px;"></div>		
Rho Immune Globulins	<p>PerformRx makes the following recommendation:</p> <div style="background-color: black; width: 100px; height: 100px; margin-top: 10px;"></div> <div style="background-color: black; width: 100px; height: 100px; margin-top: 10px;"></div> <div style="background-color: black; width: 100px; height: 100px; margin-top: 10px;"></div> <p>.CHC:</p> <ul style="list-style-type: none"> • Remove the prior authorization for WinRho, Rhophylac, and HyperRHO due 	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Kelly Martin</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>to the low utilization and high prior authorization approval rate.</p> <p>█ █ █ █ █</p>		
B. Single Products			
Ctexli	<p>PerformRx makes the following recommendation:</p> <p>█ █ █ █ █</p> <p>█ █ █ █ █</p> <p>█ █ █ █ █</p> <p>█ █ █ █ █</p> <p>█/CHC: <ul style="list-style-type: none"> • Maintain Ctexli as T4 with a prior authorization requirement. </p>	<p>Committee approved as recommended:</p> <p>Motion: David Batluck Second: Tracey Davis</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<ul style="list-style-type: none"> • Approve the newly developed Ctexli prior authorization criteria. <p>[REDACTED]</p>		
Encelto	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: David Batluck Second: Tracey Davis</p> <p>*Christopher Antypas: asked about 2nd authorization approval.</p> <p>*Sarah: Dosed 1 implant per lifetime.</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED].CHC:</p> <ul style="list-style-type: none"> • Maintain Encelto as T4 with a prior authorization requirement. • Approve the newly developed Encelto prior authorization criteria. <p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED]</p>		
Vykat XR	<p>PerformRx makes the following recommendation:</p> <p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: David Batluck Second: Tracey Davis</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>     </p> <p>  CHC: <ul style="list-style-type: none"> • Maintain Vykot XR as T4 with a prior authorization requirement. • Approve the newly developed Vykot XR prior authorization criteria. </p> <p>     </p>		
	<p>  </p> <p>     </p> <p>    </p>	<p>  </p> <p>  </p>	<p>  </p>

	<ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] 		
8. New Products			
	<p>PerformRx makes the following recommendation:</p> <p>Add to Specialty Tier 4 with drug specific PA for █/CHC:</p> <ul style="list-style-type: none"> • Crenessity • Glassia • Imaavy • Livmarli • Vanrafia • Vyvgart Hytrulo 	<p>Committee approved as recommended:</p> <p>Motion: Tracey Davis Second: David Batluck</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

<div data-bbox="459 480 1043 570"> <div data-bbox="459 480 1043 540">[REDACTED]</div> <div data-bbox="508 540 667 570">[REDACTED]</div> </div> <div data-bbox="459 594 997 688"> <div data-bbox="459 594 997 657">[REDACTED]</div> <div data-bbox="508 657 688 688">[REDACTED]</div> </div> <div data-bbox="459 712 1071 771"> <p>Add to the supplemental Tier 3 for [REDACTED]/CHC:</p> <ul style="list-style-type: none"> Midazolam-Sodium Chloride </div> <div data-bbox="459 800 1018 894"> <div data-bbox="459 800 1018 865">[REDACTED]</div> <div data-bbox="508 865 711 894">[REDACTED]</div> </div> <div data-bbox="459 919 1047 1011"> <div data-bbox="459 919 1047 982">[REDACTED]</div> <div data-bbox="508 982 735 1011">[REDACTED]</div> </div> <div data-bbox="459 1036 1052 1154"> <p>Add to the supplemental Tier 3 with a quantity limit for [REDACTED]/CHC:</p> <ul style="list-style-type: none"> Paxlovid Promethazine </div> <div data-bbox="459 1183 997 1307"> <div data-bbox="459 1183 997 1248">[REDACTED]</div> <div data-bbox="508 1248 756 1307">[REDACTED]</div> </div> <div data-bbox="459 1331 875 1421"> <div data-bbox="459 1331 875 1395">[REDACTED]</div> <div data-bbox="508 1395 718 1421">[REDACTED]</div> </div>		
--	--	--

	<div data-bbox="501 456 791 725"> </div> <p>Remain non-formulary/non-preferred for <div data-bbox="457 776 770 808"> </div> /CHC <div data-bbox="630 776 770 808"> </div>: <ul style="list-style-type: none"> • Enflonsia • Zevaskyn <p>Remain non-formulary/non-preferred for <div data-bbox="457 924 858 958"> </div> /CHC, <div data-bbox="630 924 858 958"> </div>: <ul style="list-style-type: none"> • Adrenalin • Combogesic • COVID-19 Flu A+B Antigen Test In Vitro Kit • Emblaveo • Emrelis • EPINEPHrine Bitartrate-NaCl • Gonal-f RFF • Insupen32G Extr3me • Marcaine • Tepylute • Vyloy • Zelsuvmi • Zevtera • Zusduri </p> </p>		
--	---	--	--

	<div>[REDACTED]</div>		
9. Prior Authorization Criteria Review			

















A. Prior Authorization Criteria Annual Review with Clinical Changes			
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
<p>Brineura</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<ul style="list-style-type: none">■ [REDACTED]■ [REDACTED] <p>■ [REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED] <p>■ CHC:</p> <ul style="list-style-type: none">• Remove the late infantile descriptor in the initial authorization section to reflect the listed package insert indication.• Update the age restriction to according to the package insert due to Brineura's expanded patient population. <p>■ [REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]		
--	---	--	--

Camzyos	PerformRx makes the following recommendation:	Committee approved as recommended:	PerformRx will update the criteria and formulary/PDL with any changes
	<div data-bbox="459 537 1058 659"> <div data-bbox="459 537 541 565">[REDACTED]</div> <div data-bbox="501 574 520 597">I</div> <div data-bbox="554 570 1058 659">[REDACTED]</div> </div> <div data-bbox="459 683 1058 805"> <div data-bbox="459 683 541 711">[REDACTED]</div> <div data-bbox="501 721 520 743">I</div> <div data-bbox="554 716 1058 805">[REDACTED]</div> </div> <div data-bbox="459 829 1058 951"> <div data-bbox="459 829 541 857">[REDACTED]</div> <div data-bbox="501 867 520 889">I</div> <div data-bbox="554 862 1058 951">[REDACTED]</div> </div> <div data-bbox="459 976 1058 1097"> <div data-bbox="459 976 541 1003">[REDACTED].CHC:</div> <ul style="list-style-type: none"> Update the initial authorization section to reflect the updated contraindications section of the Camzyos package insert </div> <div data-bbox="459 1122 1058 1243"> <div data-bbox="459 1122 541 1149">[REDACTED]</div> <div data-bbox="501 1159 520 1182">I</div> <div data-bbox="554 1154 1058 1243">[REDACTED]</div> </div>	<p data-bbox="1098 537 1465 618"> Motion: Christopher Antypas Second: Andrew Peterson : </p> <div data-bbox="1098 1268 1444 1333">[REDACTED]</div> <div data-bbox="1098 1357 1465 1414">[REDACTED]</div>	<div data-bbox="1514 1268 1982 1333">[REDACTED]</div>

	<p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED]</p>		
Daybue	<p>PerformRx makes the following recommendation:</p> <p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED].CHC:</p> <ul style="list-style-type: none"> • Update the prescriber restriction to also include a geneticist. <p>█ [REDACTED]</p> <p>█ [REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

<p>Ileal bile acid transporter inhibitor (IBAT)</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED].CHC:</p> <ul style="list-style-type: none"> • Approve the Ileal bile acid transporter inhibitor (IBAT) prior authorization criteria with no clinical changes. <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>
<p>Pyruvate Kinase Activators</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>   </p> <p>    </p> <p>    </p> <p>  .CHC: <ul style="list-style-type: none"> Update criteria to include label update regarding monitoring liver function monthly for the first 6 months of treatment. </p> <p>    </p>	<p>Second: Andrew Peterson</p>	
			

	<ul style="list-style-type: none"> <div> <div></div> <div></div> </div> 	<div></div>	
<div></div>	<ul style="list-style-type: none"> <div> <div></div> <div></div> </div> <div> <div></div> <div></div> </div> <div> <div></div> <div></div> </div> <div> <div></div> <div></div> </div> <div> <div></div> <div></div> </div> <div> <div></div> <div></div> </div> 	<div></div> <div></div>	<div></div>
	<p>PerformRx makes the following recommendation:</p>	<p>Committee approved as recommended:</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

<p>Lenmelyd</p>	<div> <div></div> <div></div> <div></div> <div></div> <div></div> <div> <div></div> <div> <p>.CHC:</p> <ul style="list-style-type: none"> • Add hematologist/oncologist as a prescriber option to the criteria. </div> <div></div> </div> </div>	<p>Motion: Christopher Antypas Second: Andrew Peterson</p>	
<div></div>	<div> <div></div> <div></div> </div>	<div></div> <div></div>	<div></div>

B. Prior Authorization Criteria Annual Review without Clinical Changes			
<div data-bbox="107 686 218 716" style="background-color: black; width: 53px; height: 18px;"></div>	<div data-bbox="558 597 966 659" style="background-color: black; width: 194px; height: 38px;"></div> <div data-bbox="459 686 525 743" style="background-color: black; width: 31px; height: 35px;"></div> <div data-bbox="558 716 1031 805" style="background-color: black; width: 225px; height: 55px;"></div> <div data-bbox="459 833 541 889" style="background-color: black; width: 39px; height: 35px;"></div> <div data-bbox="558 862 1031 951" style="background-color: black; width: 225px; height: 55px;"></div> <div data-bbox="459 979 541 1036" style="background-color: black; width: 39px; height: 35px;"></div> <div data-bbox="558 1008 1031 1097" style="background-color: black; width: 225px; height: 55px;"></div> <div data-bbox="459 1125 541 1182" style="background-color: black; width: 39px; height: 35px;"></div> <div data-bbox="558 1154 1031 1243" style="background-color: black; width: 225px; height: 55px;"></div> <div data-bbox="459 1271 541 1328" style="background-color: black; width: 39px; height: 35px;"></div> <div data-bbox="558 1300 1031 1390" style="background-color: black; width: 225px; height: 55px;"></div>	<div data-bbox="1138 597 1442 659" style="background-color: black; width: 145px; height: 38px;"></div> <div data-bbox="1096 686 1463 743" style="background-color: black; width: 175px; height: 35px;"></div>	<div data-bbox="1673 626 1827 659" style="background-color: black; width: 73px; height: 20px;"></div>

	<ul style="list-style-type: none"> <ul style="list-style-type: none"> [REDACTED] 		
<ul style="list-style-type: none"> <ul style="list-style-type: none"> [REDACTED] 	<ul style="list-style-type: none"> <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] 	<ul style="list-style-type: none"> <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] 	<ul style="list-style-type: none"> <ul style="list-style-type: none"> [REDACTED]
Anti-FGF23 Monoclonal Antibodies	<p>PerformRx makes the following recommendation:</p> <ul style="list-style-type: none"> <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	<p>No Changes</p>

	<ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] • [REDACTED].CHC: <ul style="list-style-type: none"> • Approve the Anti-FGF23 Monoclonal Antibodies prior authorization criteria with no clinical changes. █ [REDACTED] 		
█ [REDACTED]	<ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] 	<ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] 	█ [REDACTED]

	<div>█</div> <div>█</div> <div>█</div> <div>█</div> <div>█</div> <div>█</div>		
B-Cell Maturation Antigen (BCMA) Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy	<p>PerformRx makes the following recommendation:</p> <div>█</div> <div>█</div> <div>█</div>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	<p>No Changes</p>

	<p>[REDACTED]</p>		
	<p>[REDACTED] [REDACTED]</p>		
	<p>[REDACTED] [REDACTED]</p>		
	<p>[REDACTED] CHC:</p> <ul style="list-style-type: none">• Approve the B-Cell Maturation Antigen (BCMA) Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy prior authorization criteria with no clinical changes.		
	<p>[REDACTED] [REDACTED]</p>		

<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
<p>Corticotropin</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	<p>No Changes</p>

	<p>I [REDACTED]</p> <p>[REDACTED].CHC:</p> <ul style="list-style-type: none"> • Approve the Corticotropin prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <p>I [REDACTED]</p>		
[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>I [REDACTED]</p> <p>[REDACTED]</p> <p>I [REDACTED]</p> <p>[REDACTED]</p> <p>I [REDACTED]</p> <p>[REDACTED]</p> <p>I [REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

██████	<div>████████████████████</div> <div>████████████████████</div> <div>██████</div> <div>█</div> <div>████████████████████</div> <div>████████████████████</div> <div>██████</div> <div>█</div> <div>████████████████████</div> <div>████████████████████</div> <div>██████</div> <div>█</div> <div>████████████████████</div> <div>████████████████████</div>	<div>████████████████████</div> <div>████████████████████</div> <div>████████████████████</div> <div>████████████████████</div>	<div>████████</div>
Duvyzat	<p>PerformRx makes the following recommendation:</p> <div>██████</div> <div>█</div> <div>████████████████████</div> <div>████████████████████</div> <div>██████</div> <div>█</div> <div>████████████████████</div> <div>████████████████████</div> <div>██████</div>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	<p>No Changes</p>

	<p>█ [REDACTED]</p> <p>[REDACTED].CHC:</p> <ul style="list-style-type: none"> • Approve the Duvyzat prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <p>█ [REDACTED]</p>		
Elevidys	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>█ [REDACTED]</p> <p>[REDACTED]</p> <p>█ [REDACTED]</p> <p>[REDACTED].CHC:</p> <ul style="list-style-type: none"> • Approve the Elevidys prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <p>█ [REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p> <p>*Manni Sethi & Christopher Antypas: spoke regarding the fatality.</p> <p>*Will keep up with future updates.</p>	No Changes
	<p>PerformRx makes the following recommendation:</p>	<p>Committee approved as recommended:</p>	No Changes

Enzyme Replacement Therapies for Fabry Disease	<p>██████████ █</p> <p>██████████ █</p> <p>██████████ █</p> <p>██████████ █</p> <p>██████████ █</p> <p>██████████ █</p> <p>██████████ █</p>	<p>Motion: Christopher Antypas Second: Andrew Peterson</p>	
--	---	--	--

	<ul style="list-style-type: none"> • Approve the Enzyme Replacement Therapies for Fabry Disease prior authorization criteria with no clinical changes. <p>[REDACTED]</p>		
Fecal Microbiota	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	No Changes

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED].CHC:</p> <ul style="list-style-type: none"> • Approve the Fecal Microbiota prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <p>[REDACTED]</p>		
Gene Therapy for Hemophilia B	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED].CHC:</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	No Changes

	<ul style="list-style-type: none"> • Approve the Gene Therapy for Hemophilia B prior authorization criteria with no clinical changes. 		
	<div> <div></div> <div></div> </div>		
	<div> <div></div> <div></div> </div>	<div> <div></div> <div></div> </div>	<div> <div></div> </div>
	<div> <div></div> <div></div> </div>	<div> <div></div> <div></div> </div>	
	<div> <div></div> <div></div> </div>		
	<div> <div></div> <div></div> </div>		
	<div> <div></div> <div></div> </div>		
	<div> <div></div> <div></div> </div>		

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>		
Increlex	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED].CHC:</p> <ul style="list-style-type: none"> • Approve the Increlex prior authorization criteria with no clinical changes. 	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	No Changes
Insulin-Like Growth Factor-1 Receptor Antagonists for Thyroid Eye Disease	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	No Changes

	<div><div></div><div></div><div></div><div></div><div></div><div></div><div>.CHC:<ul style="list-style-type: none">• Approve the Insulin-Like Growth Factor-1 Receptor (Igf-1r) Antagonists for</div></div>		
--	---	--	--

	<p>Thyroid Eye Disease prior authorization criteria with no clinical changes.</p> <p>[REDACTED]</p>		
Joenja	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>CHC:</p> <ul style="list-style-type: none"> Approve the Joenja prior authorization criteria with no clinical changes. <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	No Changes

	I [REDACTED]		
Leqembi	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED] I [REDACTED]</p> <p>[REDACTED] I [REDACTED]</p> <p>[REDACTED] I [REDACTED]</p> <p>[REDACTED] I [REDACTED]</p> <p>[REDACTED] I [REDACTED]</p> <p>[REDACTED] I [REDACTED]</p> <p>[REDACTED].CHC:</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	No Changes

	<ul style="list-style-type: none"> Approve the Leqembi prior authorization criteria with no clinical changes. 		
Mucopolysaccharidosis II Agents (Elaprase)	<p>PerformRx makes the following recommendation:</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	No Changes

	<p>[REDACTED]</p> <p>[REDACTED].CHC:</p> <ul style="list-style-type: none"> • Approve the Mucopolysaccharidosis II (Hunter Syndrome) Agents prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <p>[REDACTED]</p>		
Omisurge	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	No Changes

	<p>█ [REDACTED]</p> <p>█.CHC:</p> <ul style="list-style-type: none"> • Approve the Omisirge prior authorization criteria with no clinical changes. <p>█ [REDACTED]</p> <p>█ [REDACTED]</p>		
[REDACTED]	<p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED]</p>	<p>█ [REDACTED]</p> <p>█ [REDACTED]</p>	<p>█ [REDACTED]</p>
[REDACTED]	<p>█ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED]</p>	<p>█ [REDACTED]</p> <p>█ [REDACTED]</p>	<p>█ [REDACTED]</p>

	<ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] 		
Rituximab	<p>PerformRx makes the following recommendation:</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	No Changes

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED].CHC:</p> <ul style="list-style-type: none"> • Approve the Rituximab prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <p>[REDACTED]</p>		
[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

	<ul style="list-style-type: none"> <ul style="list-style-type: none"> [REDACTED] 		
[REDACTED]	<ul style="list-style-type: none"> <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] 	<ul style="list-style-type: none"> [REDACTED] [REDACTED] 	<ul style="list-style-type: none"> [REDACTED]
Skyclarys	<p>PerformRx makes the following recommendation:</p> <ul style="list-style-type: none"> <ul style="list-style-type: none"> [REDACTED] <ul style="list-style-type: none"> [REDACTED] 	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	<p>No Changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>CHC:</p> <ul style="list-style-type: none"> • Approve the Skyclarys prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <p>[REDACTED]</p>		
Synagis	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	No Changes

	<p>[REDACTED]</p> <p>[REDACTED].CHC:</p> <ul style="list-style-type: none"> • Approve the Synagis prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <p>[REDACTED]</p>		
Urea Cycle Disorder Agents	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	No Changes

<p>Verquvo</p>	<p>PerformRx makes the following recommendation:</p> <p>█ █ [REDACTED]</p> <p>█ █ [REDACTED]</p> <p>█ █ [REDACTED]</p> <p>█.CHC: <ul style="list-style-type: none"> • Approve the Verquvo prior authorization criteria with no clinical changes. </p> <p>█ █ [REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	<p>No Changes</p>
<p>Vioice</p>	<p>PerformRx makes the following recommendation:</p> <p>█ █ [REDACTED]</p> <p>█ █ [REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	<p>No Changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED].CHC:</p> <ul style="list-style-type: none"> • Approve the Vioice prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <p>[REDACTED]</p>		
Vimizim	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended:</p> <p>Motion: Christopher Antypas Second: Andrew Peterson</p>	No Changes

	<p>.CHC:</p> <ul style="list-style-type: none"> Approve the Vimizim prior authorization criteria with no clinical changes. 		
[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED].CHC:</p> <ul style="list-style-type: none"> • Approve the Xolremdi prior authorization criteria with no clinical changes. <p>[REDACTED]</p>		
[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

	<p>I [REDACTED]</p>		
[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
10. Recalls	<p>Date: 7/15/2025</p> <p>Manufacturer: Nostrum Laboratories, Inc.</p> <p>Product Name: Sucralfate Tablets USP 1 Gram</p> <p>Reason: Company closure and discontinuation of quality activities.</p>		
11. Adjourn	<p>The meeting adjourned at 7:07 PM EST</p> <p>Motion: Kelly Martin Second: Rani Whitfield</p>		Manni Sethi
	<p>Next P&T Meeting October 27th, 2025 6:00pm- 8:00pm EST</p>		

Signed: Jeffrey K. Allen Ph.D.

Date: 10/27/2025